Search results for "therapeutic effect"

showing 10 items of 64 documents

Effect of Cell Line and Differentiation on the Oxygenation Status of Experimental Sarcomas

1997

Since the measurement of tumor oxygenation status and the fraction of hypoxia within tumor tissue by computerized pO2-histography [10] has become increasingly im-portant in the clinical setting, many studies on tumor oxygenation in different experimental malignancies as well as in various human tumors have been carried out. Because pO2-histography is an invasive technique, this method has been used in humans mostly in superficial primary tumors and lymph node metastases [1,3,10] (for a review see [9]). Experimental studies in animals have been carried out on a wide range of isotransplanted rodent sarcomas or carcinomas [2,4,6–8,11] and of xenotransplanted human tumors [6]. The results obtai…

HyperoxiaPathologymedicine.medical_specialtybusiness.industryTherapeutic effectOxygenationTumor OxygenationHypoxia (medical)medicine.anatomical_structuremedicineRadiosensitivitymedicine.symptomRespiratory systembusinessLymph node
researchProduct

Nanotechnology applications for the therapy of liver fibrosis.

2013

Chronic liver diseases represent a major global health problem both for their high prevalence worldwide and, in the more advanced stages, for the limited available curative treatment options. In fact, when lesions of different etiologies chronically affect the liver, triggering the fibrogenesis mechanisms, damage has already occurred and the progression of fibrosis will have a major clinical impact entailing severe complications, expensive treatments and death in end-stage liver disease. Despite significant advances in the understanding of the mechanisms of liver fibrinogenesis, the drugs used in liver fibrosis treatment still have a limited therapeutic effect. Many drugs showing potent ant…

Liver CirrhosisSettore MED/09 - Medicina InternaAntifibrotic drugs CirrhosiLiver fibrosisChemistry PharmaceuticalLiver fibrosisCellPharmacologyBioinformaticsAntifibrotic drugsLiver diseaseNanoparticleHepatic stellate cellsIn vivoFibrosisMedicineNanotechnologyAnimalsHumansTopic HighlightAdverse effectHepatic stellate cellDrug Carriersbusiness.industryTherapeutic effectGastroenterologyLiver fibrosiGeneral Medicinemedicine.diseasemedicine.anatomical_structureNanomedicineTreatment OutcomeCirrhosisHepatic stellate cellNanoparticlesbusinessWorld journal of gastroenterology
researchProduct

Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice.

2012

Stroke represents an attractive target for stem cell therapy. Although different types of cells have been employed in animal models, a direct comparison between cell sources has not been performed. The aim of our study was to assess the effect of human multipotent adult progenitor cells (hMAPCs) and human mesenchymal stem cells (hMSCs) on endogenous neurogenesis, angiogenesis and inflammation following stroke. BALB/Ca-RAG 2(-/-) γC(-/-) mice subjected to FeCl(3) thrombosis mediated stroke were intracranially injected with 2 × 10(5) hMAPCs or hMSCs 2 days after stroke and followed for up to 28 days. We could not detect long-term engraftment of either cell population. However, in comparison w…

MaleAnatomy and PhysiologyMousemedicine.medical_treatmentCell therapyMiceCell MovementMolecular Cell BiologyNeurobiology of Disease and RegenerationMedicineMultidisciplinaryNeuronal MorphologyNeurogenesisQRBrainInfarction Middle Cerebral ArteryAnimal ModelsStem-cell therapyStrokeAdult Stem Cellsmedicine.anatomical_structureNeurologyMedicineResearch ArticleAdult stem cellCell PhysiologyHistologyCell SurvivalCerebrovascular DiseasesScienceTherapeutic effectsNeurophysiologyNeovascularization PhysiologicSubventricular zoneMesenchymal Stem Cell TransplantationNeurological SystemModel OrganismsAnimalsHumansProgenitor cellBiologyTransplantationbusiness.industryMultipotent Stem CellsMesenchymal stem cellMultipotent Stem CellCellular NeuroscienceImmunologyCancer researchMolecular NeurosciencebusinesshMAPC and hMSCNeurosciencePLoS ONE
researchProduct

Pregabalin as add-on treatment to botulinum toxin in idiopathic hemifacial spasm

2007

Botulinum toxin (BTX) is the medical therapy of choice in hemifacial spasm (HFS). However, in some patients, its therapeutic effect is insufficient. ### Patient 1. A 64-year-old man with a 10-year history of left-sided HFS was treated with BTX over a period of 6 years with good results. However, in the last 2 years the spasms were never sufficiently relieved by BTX. The patient felt significantly impaired, but declined to undergo neurosurgical intervention. The EDB test showed a decrease in the CMAP amplitude of 60%. Without changing the BTX regime, pregabalin (initially 75 mg/day increased every 5 days by 75 mg to 150 mg twice daily) was added for a 1-month trial period in the absence of a…

MaleBotulinum ToxinsPregabalinPregabalinPhysiology (medical)medicineHumansHemifacial SpasmAdverse effectgamma-Aminobutyric AcidAnti-Dyskinesia Agentsbusiness.industryTherapeutic effectMiddle Agedmedicine.diseaseBotulinum toxinSensory SystemsDiscontinuationDrug CombinationsTreatment OutcomeAdd on treatmentNeurologyAnesthesiaAnticonvulsantsFemaleNeurology (clinical)businessMedical therapymedicine.drugHemifacial spasmNeurology
researchProduct

Piracetam counteracts the effects of amitriptyline on inhibitory avoidance in CD1 mice.

2005

The purpose of the present work was to study the effects of amitriptyline on animal cognition in relation to some characteristics of its therapeutic effects. The modulation of acute and chronic effects of amitriptyline on inhibitory avoidance in male and female mice by piracetam was investigated. In Experiment 1, mice were subjected to the training phase of inhibitory avoidance conditioning 60 min after acute piracetam (100 mg/kg) or physiological saline administration. Immediately after the behavioural task, they received a single injection of the tricyclic antidepressant amitriptyline (30 mg/kg) or physiological saline. Twenty-four hours later, subjects were tested for avoidance. In Exper…

MaleElevated plus mazemedicine.medical_specialtymedicine.drug_classAmitriptylineTricyclic antidepressantPharmacologyAntidepressive Agents TricyclicInhibitory postsynaptic potentialDrug Administration ScheduleStatistics NonparametricBehavioral NeuroscienceMiceSex FactorsMemorymedicineAvoidance LearningAnimalsAmitriptylineDrug InteractionsPsychiatryNootropic AgentsAnalysis of VarianceReactive inhibitionTherapeutic effectPiracetamReactive InhibitionPiracetamFemaleAnalysis of variancePsychologymedicine.drugBehavioural brain research
researchProduct

Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors

2019

Combinations of therapies may enhance therapeutic effects without significantly increasing the incidence of adverse events. However, there are few data regarding survival after concomitant chemotherapy and peptide receptor radionuclide therapy (PRRT) with [Lu]Lu-octreotate in patients with neuroendocrine tumors (NETs). Thus, we explored the outcome of this combination of therapies.Fifteen patients with somatostatin receptor-positive, rapidly progressive G2/G3 NETs during chemotherapy or PRRT alone from 2 German cancer centers were included in the retrospective analysis. The patients received a combination of PRRT and chemotherapy with temozolomide (n = 3) or temozolomide plus capecitabine (…

MaleOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyPeptide receptormedicine.medical_treatmentNeuroendocrine tumorsOctreotide030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographyInternal medicineOrganometallic CompoundsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingAdverse effectCapecitabineAgedChemotherapybusiness.industryIncidence (epidemiology)Therapeutic effectChemoradiotherapyGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumors030220 oncology & carcinogenesisConcomitantRadionuclide therapyFemaleRadiopharmaceuticalsbusinessClinical Nuclear Medicine
researchProduct

Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.

2009

Purpose. To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines. Methods. The study, double-blinded, randomised, assessed intravenous infusion of LPC 1.2 g/day in combination with PGE-1, 60 mg/day (LPC group: 37 patients), or PGE-1 only (control group: 38 patients) in a total of 75 patients suffering from CLI. Treatment duration was 20 days. We evaluated rest pain, maximum walking distance (MWD) and skin ulcer size. Results. In both groups we observed a significant reduction in pain score and ulcer size and an increase in MWD. In the patients treated with the combination, the improvement was greater…

MaleSettore MED/09 - Medicina InternaCardiotonic AgentsVasodilator AgentsProstaglandin E1IschemiaPainWalkinglaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawIschemiaCarnitinemedicineHumansPharmacology (medical)CarnitineAlprostadilProstaglandin E1Infusions IntravenousAgedPharmacologyLegCritical Limb Ischemiabusiness.industryTherapeutic effectLeg UlcerDrug SynergismGeneral MedicineCritical limb ischemiaL-PropionylcarnitineSkin ulcerMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareTreatment OutcomechemistryAnesthesiaChronic Diseaselipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugCardiovascular drugs and therapy
researchProduct

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

2014

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). METHODS: This was a prospective multicenter randomized nonblinded trial. RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was…

MaleVascular Endothelial Growth Factor AVisual Acuity/drug effectsVisual acuitygenetic structuresVisual AcuityAngiogenesis Inhibitorslaw.inventionBevacizumab/therapeutic use0302 clinical medicineRandomized controlled triallawMyopiaMedicineProspective StudiesProspective cohort studyPathological myopiaAged 80 and overMiddle AgedSensory SystemsBevacizumabVascular endothelial growth factor AChoroidal neovascularizationIntravitreal InjectionsMyopia DegenerativeFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabNeuroscience(all)CNVBevacizumab; CNV; Pathological myopia; Ranibizumab.Antibodies Monoclonal HumanizedRanibizumab/therapeutic use03 medical and health sciencesCellular and Molecular NeuroscienceOphthalmologyRanibizumabVascular Endothelial Growth Factor A/antagonists & inhibitorsHumansAngiogenesis Inhibitors/therapeutic useIntravitreal bevacizumabAgedpathological myopia CNV bevacizumab ranibizumabSettore MED/30 - Malattie Apparato Visivobusiness.industryTherapeutic effectChoroidal Neovascularization/drug therapyeye diseasesChoroidal NeovascularizationOphthalmologyRegimen030221 ophthalmology & optometryMyopia Degenerative/drug therapysense organsRanibizumabbusiness030217 neurology & neurosurgeryFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

The use of corticosteroids in home palliative care

2001

Evidence for the effectiveness of corticosteroids in palliative care is anecdotal, and more information is required. From January to December 1999 a total of 376 consecutive patients admitted to a home palliative care program were longitudinally surveyed. Patients who started a corticosteroid treatment after admission on the basis of common indications prescribed by their home care physicians were selected. Fifty patients were enrolled in the study. Dexametha-sone, in doses ranging from 4 to 16 mg, was the drug of choice. Corticosteroids were found to be effective in anorexia, weakness, headache, and nausea and vomiting. The reduction of symptom intensity was achieved in less than 3 days on…

MaleWeaknessPediatricsmedicine.medical_specialtyPalliative careNauseaLongitudinal epedemiological studyAnorexiaHome palliative careDexamethasoneStatistics NonparametricmedicineHumansCorticosteroidLongitudinal StudiesAdverse effectIntensive care medicineGlucocorticoidsNursing (all)2901 Nursing (miscellaneous)AgedAged 80 and overbusiness.industryPalliative CareTherapeutic effectMiddle Agedmedicine.diseaseHome Care ServicesBowel obstructionItalyOncologyVomitingFemalemedicine.symptombusiness
researchProduct

Cannabidiol prevents several of the behavioral alterations related to cocaine addiction in mice.

2021

Abstract Cocaine dependence is a highly prevalent disease in modern society and lacks an effective treatment. Cannabidiol (CBD), a major non-psychoactive constituent of Cannabis sativa, has been shown to be a promising tool in the management of some neuropsychiatric disorders, including cocaine abuse. However, its therapeutic effects on the behavioral outcomes related to cocaine addiction remain unclear. The present research evaluates the effects of CBD (30, 60 and 120 mg/kg; injected intraperitoneally) on the acquisition, expression, extinction and reinstatement of cocaine (10 mg/kg)-induced conditioned place preference (CPP; Study 1); cocaine (25 mg/kg)-induced locomotor stimulation (Stud…

Malemedia_common.quotation_subjectConditioning ClassicalPharmacologyHyperkinesisCocaine dependenceExtinction Psychological03 medical and health sciencesCocaine-Related DisordersMice0302 clinical medicineCocainemedicineAnimalsCannabidiolBiological Psychiatrymedia_commonPharmacologyDose-Response Relationship Drugbusiness.industryAddictionTherapeutic effectExtinction (psychology)Abstinencemedicine.diseaseConditioned place preferenceTail suspension test030227 psychiatrySubstance Withdrawal SyndromeMice Inbred C57BLbusinessCannabidiolInjections IntraperitonealLocomotionmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct